tirzepatide lawsuit update Eli Lilly joins FDA as Defendant in Over Shortage court decision on tirzepatide Lawsuit

Generic semaglutide must meet the same standards for safety and effectiveness as Ozempic

Both waive any recovery on the 2L Facility, the approximately $260 million second-lien claim held by National Distributing Company, Inc

The only way to guarantee the safety, efficacy and quality of a medication is by FDA-approval

Also, the previous literature dominated by older trials from specific regions (mostly Europe), which may limit generalizability to other settings

This has led to a steep increase in use and prescription of these drugs, resulting in 2-3% of Americans reportedly being on them

A 6-week wait burns about $222 before any medication ships